CALQUENCE 100 mg/1

CALQUENCE 100 mg tablets contain acalabrutinib, a targeted therapy used in managing certain blood cancers. This oral medication is designed to inhibit specific enzymes involved in cancer cell growth.

CALQUENCE 100 mg tablets are primarily used in the treatment of specific types of blood cancers. Acalabrutinib works by targeting and inhibiting enzymes that play a role in the growth and survival of cancer cells. This medication is often prescribed for conditions where these enzymes are overactive, contributing to the progression of the disease. Patients should consult their healthcare provider to determine if CALQUENCE is suitable for their condition.

Common effects of CALQUENCE 100 mg tablets may include fatigue, headache, and diarrhea. Some individuals might experience bruising or bleeding more easily. It's important to monitor for any unusual symptoms and report them to a healthcare professional.

CALQUENCE 100 mg tablets should be handled with care and stored as directed. Patients should avoid activities that increase the risk of bleeding or injury while taking this medication. Regular blood tests may be recommended to monitor for potential side effects.

CALQUENCE 100 mg tablets may interact with certain medications, including those that affect liver enzymes. It's important to inform your healthcare provider about all medications you are taking to avoid potential interactions. Alcohol and other substances that affect blood clotting should be used with caution.